⬅ # 968 Norman Braman|# 970 Thomas Tull ➡

# 969 Cen Junda 

$3.51B

Real Time Net Worth
as of 12/22/2024
-$63.7M (-1.81%)

# 969 Cen Junda 

$3.51B

Real Time Net Worth
as of 12/22/2024
-$63.7M (-1.81%)
OccupationPartial Owner, Jiangsu Hengrui Medicine; Partial Owner, Hansoh Pharmaceutical Group
Source of WealthPharmaceuticals
Age60
ResidenceLianyungang, China
EducationDoctorate, Zhejiang University
Age-Adjusted Net Worth$3.51B
Cen Junda
Cen Junda
China
Net worth: $3.51B

Self-Made Score 

TAG Heuer Luxury Watch

Wealth History

Hover or tap to reveal net worth by year
Loading Chart

Biography

Overview

Cen Junda's fortune primarily derives from his substantial stakes in Jiangsu Hengrui Medicine and Hansoh Pharmaceutical Group, both major players in the pharmaceutical industry in China.
Hansoh Pharmaceutical Group, founded in 1995 by Zhong Huijuan, is renowned for manufacturing and selling various types of medicine, particularly psychotropic drugs.
Jiangsu Hengrui Medicine, established in 1970 as Lianyungang Pharmaceutical Factory, has evolved into China's largest listed pharmaceutical company, specializing in cancer-treating antineoplastics, cardiovascular medication, painkillers, antibiotics, and related products.

Early Life and Education

Cen Junda holds degrees from Zhejiang University and the China State Institute of Pharmaceutical Industry.
His educational background equipped him with a strong foundation for his future endeavors in the pharmaceutical sector.

Jiangsu Hengrui Medicine

Cen Junda is a significant shareholder of Jiangsu Hengrui Medicine, a leading Chinese producer of anti-cancer drugs.
Originally established in 1970 as Lianyungang Pharmaceutical Factory, it was later rebranded as Jiangsu Hengrui Pharmaceuticals Company Ltd., becoming the largest listed pharmaceutical company in China.
In 2022, Jiangsu Hengrui Medicine recorded impressive revenue of 21.3 billion yuan ($3.2 billion), highlighting its substantial growth and market presence.

Hansoh Pharmaceutical Group

Cen Junda owns a stake in Hansoh Pharmaceutical Group, a prominent pharmaceutical company founded in 1995 by Zhong Huijuan.
Hansoh Pharmaceutical Group gained recognition for its diverse range of medicines and psychotropic drugs, solidifying its position as a key player in China's pharmaceutical landscape.
The company went public on the main board of the Hong Kong Stock Exchange in June 2019 and was later included in the Hang Seng Index in August 2022, underscoring its financial significance.

Research and Development

Jiangsu Hengrui Medicine is committed to advancing pharmaceutical research and development, with a particular focus on cutting-edge technologies and innovative treatments.
The company established research and development offices in Princeton, New Jersey, and Basel, Switzerland, in 2020, signaling its global reach and commitment to scientific excellence.
Clinical trials conducted by Jiangsu Hengrui Medicine encompass a broad spectrum of medical fields, including cancer treatment, metabolic diseases, autoimmune diseases, HIV treatment, and analgesia, showcasing its dedication to addressing diverse healthcare challenges.

Cen Junda's Wealth is Equivalent to:

2,700,539 Herman Miller Aeron Chairs

Herman Miller Aeron Chair

663,765 Gold Bars (50 gram)

24K Solid 50g Gold Ingot

35,853 Tiny Homes

Tiny House, Two Bedroom Solar Prefab Home

How long would it take you to become as rich as Cen Junda?

If you started with $10,000 and invested an additional $500 each month at a 42.82% CAGR, it would take you 5 years to reach Cen Junda's net worth of $3.51B.

Is this realistic? It depends how closely the VIX-TA-Macro Advanced model performs to its history in the future. Since Grizzly Bulls launched on January 1, 2022, it's returned 67.72% compared to 25.94% for the S&P 500 benchmark.

Enter data in all but one field below, then calculate the missing value

Cen Junda is very wealthy, but what's stopping you from reaching that same level of success? As summarized in our five fundamental rules to wealth building, becoming wealthy in a modern capitalist economy is not complicated. There's actually only three variables:

  1. Your starting capital
  2. Your earnings after expenses
  3. The compound annual growth rate (CAGR) of your savings

Most people start with zero or very little, so if you weren't born into wealth, don't fret! The majority of the fortunate folks listed in our Grizzly Bulls’ Billionaires Index came from middle class or lower backgrounds. The most distinguishing characteristic of the group is their ability to consistently earn a high CAGR on their savings.

Every billionaire has a unique strategy to achieve high CAGR. For Cen Junda, Pharmaceuticals is the primary source. Whether you choose to invest your savings in your own businesses or the businesses of others is not as important. The salient piece of the puzzle is ensuring that your hard-earned savings are generating sufficient CAGR to reach your long term goals.

Most people simply invest their money in index funds and call it a day. There's nothing wrong with this approach, but it guarantees relative mediocrity. To achieve greatness, you need to invest your money to earn higher than average returns. In the long run, better investors will always finish ahead of better earners.

Source: Grizzly Bulls reporting

Methodology: Grizzly Bulls' Billionaires Index is a daily ranking of the world's billionaires and richest people. Grizzly Bulls strives to provide the most accurate net worth calculations available. We pull data from public equity markets, SEC filings, public real estate records, and other reputable sources.

The index is dynamic and updates daily at the close of U.S. stock market trading based on changes in the markets, economy, and updates to Grizzly Bulls' proprietary algorithm of personal wealth calculation. Stakes in public companies are tracked daily based on the relevant closing prices of the underlying securities. Additionally, stakes in private companies, cash, real estate, and other less easily valued assets are updated periodically through careful analysis of insider transactions, comparable public company sales / EBITDA multiples, etc.

Affiliate Disclosure: Some of the links on this page are affiliate links. This means that, at no additional cost to you, we may earn a commission if you click through and make a purchase. We only recommend products or services we believe will add value to our readers.

Edited by: Lee Bailey